EQT announced it has agreed to acquire Corza Biosurgery from Corza Medical, bringing the TachoSil biosurgery business into its portfolio as it looks to build a larger global platform in surgical biologics. The transaction includes TachoSil, a biologic hemostat and tissue-sealing patch used in complex surgical procedures across multiple specialties. Financial terms of the acquisition were not disclosed.
TachoSil is used by surgeons in more than 50 countries and has been adopted across cardiovascular, neurological, hepatic, thoracic, and other surgical specialties. Designed to both control bleeding and seal tissue, the biologic patch is supported by more than two decades of manufacturing expertise and an extensive clinical evidence base, including over 540 published clinical trial studies. Corza Biosurgery employs approximately 400 people worldwide and operates a specialized manufacturing facility in Linz, Austria.
EQT believes demand for advanced surgical technologies will continue to grow as healthcare providers seek to improve patient outcomes, reduce complications, and increase operating room efficiency. The firm noted that rising surgical volumes driven by aging populations, increasing rates of chronic disease, and advances in surgical techniques create favorable long-term market conditions for TachoSil.
Following the acquisition, EQT plans to invest in expanding the company’s commercial capabilities, increasing adoption in the United States, pursuing additional clinical indications, and accelerating growth in underpenetrated international markets. The private equity firm also intends to strengthen the standalone business through innovation while using mergers, acquisitions, and strategic partnerships to build a broader biosurgery platform.
As part of the transaction, Sheri McCoy, former Chair of Johnson & Johnson’s Surgical Care Group, will become Chair of the Board of the standalone company following the deal’s completion.
The acquisition is expected to close during the fourth quarter of 2026, subject to customary regulatory approvals and closing conditions. Piper Sandler served as financial advisor to EQT, while Latham & Watkins acted as legal counsel.
KEY QUOTES:
“TachoSil has a unique clinical value proposition that improves patient outcomes across critical surgical procedures around the world, and is backed by strong physician preference and extensive clinical evidence. We are deeply impressed by the dedication of the Corza Biosurgery team and look forward to partnering with them to expand access globally, invest in growth, and further strengthen the Company’s position as a leading biosurgery platform.”
Ethan Waxman, Partner at EQT
“We are excited to partner with EQT during a pivotal moment for TachoSil. EQT’s healthcare expertise, operational resources, and commitment to long-term growth align perfectly with our vision to expand access to TachoSil globally and advance innovation.”
Thierry Leclercq, President of Corza Biosurgery
